chronic rhinosinusitis

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Pension funds S.Korea’s NPS investment arm suffers from chronic understaffing

South Korea’s largest institutional investor, the National Pension Service (NPS), managing 1,150 trillion won ($870.6 billion) in assets, stru...

Bio & Pharma Kakao launches AI-based blood sugar management solution

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

Bio & Pharma Celltrion applies for approval of Xolair biosimilar in Canada

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...

Bio & Pharma Dong-A ST, UMass to jointly research for gene therapy

South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...

Bio & Pharma GI Innovation seeks to license allergy therapy to Japan in 2023

South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...

Economy S.Korea’s chronic disease: Decline in youth employment

The number of young workers in South Korea fell for a sixth straight month in April to its lowest point in more than two years, deepening concerns t...

Bio & Pharma Humasis participates Dubai MEDLAB Middle East 2023

South Korean medical devices maker, Humasis Co., is participating in the MEDLAB Middle East 2023 event taking place at the Dubai World Trade Center ...

Healthcare KT taps Vietnam for digital healthcare and AI-powered diagnosis

KT Corp., a major telecommunications company in South Korea, is set to enter the Vietnamese healthcare market with a pilot telemedicine service an...